We show that treatment with ceritinib dose-dependently inhibited growth and survival response of a panel of CCA cell lines more potently than crizotinib, capmatinib, and combinations of gemcitabine and cisplatin, without inhibiting cMet phosphorylation. This evidence concerns the gene MET and cholangiocarcinoma.